ADMA Biologics Inc (ADMA)

Fixed asset turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 426,454 382,809 330,245 283,177 258,216 234,293 208,108 181,890 154,079 130,481 110,072 93,998 80,944 68,517 58,112 48,069 42,220 40,301 37,248 36,021
Property, plant and equipment US$ in thousands 54,707 53,694 54,326 55,317 53,835 54,815 56,306 57,371 58,261 56,946 54,951 53,220 50,935 48,394 46,487 44,176 41,593 39,623 37,373 35,061
Fixed asset turnover 7.80 7.13 6.08 5.12 4.80 4.27 3.70 3.17 2.64 2.29 2.00 1.77 1.59 1.42 1.25 1.09 1.02 1.02 1.00 1.03

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $426,454K ÷ $54,707K
= 7.80

The fixed asset turnover ratio for ADMA Biologics Inc has been showing a consistent increasing trend over the periods reported. The ratio has grown from 1.03 in March 2020 to 7.80 in December 2024. This indicates that the company is generating more revenue per dollar invested in fixed assets. The increasing trend suggests improved efficiency in utilizing its fixed assets to generate sales, which is a positive sign of operational performance. It shows that ADMA Biologics Inc has been successful in effectively managing and utilizing its fixed assets over time to drive revenue growth.